FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase II/III Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s Precision PromiseSM Phase II/III adaptive platform trial, which evaluated pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with mPDAC.